FOLH1 and prostate cancer: Farolfi et al. reported the diagnostic performance of 68Ga-PSMA PET/CT in 119 prostate cancer patients with biochemical recurrence retrospectively, whose PSA levels are the range 0.2–0.5 ng/ml at the time of PET.